Pharmafile Logo

ADjoin LTE

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

Almirall celebrates new offices in China to advance innovation in dermatology

The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Lilly announces acquisition of Ventyx Biosciences for around $1.2bn

Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

- PMLiVE

Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

Some patients found the treatment reduced itch and sleep disturbance within just two days

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Lilly announces plans for $6bn US manufacture facility

The site is the third of four new US sites that Lilly has announced

- PMLiVE

Lilly and MeiraGTx partner in $475m ophthalmology deal

The companies will develop and commercialise therapies for genetic conditions

- PMLiVE

Lilly announces agreement with US government to lower patient costs

The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

- PMLiVE

Lilly announces plan for new $3bn facility to boost manufacturing in Europe

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

- PMLiVE

Lilly to invest $1.2bn in Puerto Rico manufacturing site

The investment will strengthen Lilly’s US manufacturing network

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links